Lupin has launched Clobazam Tablets, 10 mg and 20 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Lupin’s Clobazam Tablets, 10 mg and 20 mg is the generic version of Lundbeck Pharms, LLC’s Onfi Tablets, 10 mg and 20 mg. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
Clobazam Tablets, 10 mg and 20 mg, had an annual sales of approximately $479 million in the US (IQVIA MAT March 2019).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
